Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001193125-16-461650
Filing Date
2016-02-12
Accepted
2016-02-12 12:44:32
Documents
2
Group Members
ESSEX WOODLANDS HEALTH VENTURES FUND V, L.P.ESSEX WOODLANDS HEALTH VENTURES FUND VIII, L.P.ESSEX WOODLANDS HEALTH VENTURES FUND VIII-A, L.P.ESSEX WOODLANDS HEALTH VENTURES FUND VIII-B, L.P.ESSEX WOODLANDS HEALTH VENTURES V, L.L.C.ESSEX WOODLANDS HEALTH VE

Document Format Files

Seq Description Document Type Size
1 SC 13G d37397dsc13g.htm SC 13G 238328
2 EX-99.1 d37397dex991.htm EX-99.1 25868
  Complete submission text file 0001193125-16-461650.txt   266254
Mailing Address 7555 GATEWAY BLVD. NEWARK CA 94560
Business Address 7555 GATEWAY BLVD. NEWARK CA 94560 510-742-3400
Revance Therapeutics, Inc. (Subject) CIK: 0001479290 (see all company filings)

EIN.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-88023 | Film No.: 161417036
SIC: 2834 Pharmaceutical Preparations

Mailing Address 21 WATERWAY AVENUE SUITE 225 THE WOODLANDS TX 77380
Business Address 21 WATERWAY AVENUE SUITE 225 THE WOODLANDS TX 77380 2813641555
Essex Woodlands Health Ventures VIII, L.L.C. (Filed by) CIK: 0001632027 (see all company filings)

EIN.: 261923296
Type: SC 13G